• Corpus ID: 23594338

Bioequivalence of allopurinol-containing tablet preparations.

@article{Barthel1999BioequivalenceOA,
  title={Bioequivalence of allopurinol-containing tablet preparations.},
  author={Wolfgang Barthel and G. H{\"u}ller and K. O. Haustein},
  journal={International journal of clinical pharmacology and therapeutics},
  year={1999},
  volume={37 3},
  pages={
          148-52
        }
}
AIM The study was undertaken to prove the bioequivalence of two allopurinol tablet preparations. SUBJECTS, MATERIALS AND METHODS The relative bioavailability of allopurinol from two tablet preparations (Uribenz vs. Zyloric 300) was estimated on 18 volunteers of both sexes in an open randomized study by administering one tablet of each preparation at an interval of 2 weeks. The plasma concentrations of allopurinol and its active metabolite oxypurinol were measured over a time-period of 72h by… 
Pharmacokinetics and comparative bioavailability of allopurinol formulations in healthy subjects
TLDR
The two allopurinol formulations were considered bioequivalent, based on the rate and extent of absorption, and both formulations were well tolerated.
Studies on Bi-Layer Osmotic Pump Tablets of Water-Insoluble Allopurinol with Large Dose: In Vitro and In Vivo
TLDR
Water-insoluble drugs with large dose can be designed to BOPT for efficacy and safety use and a good in vitro–in vivo correlation of allopurinol was proved.
Higher Therapeutic Plasma Oxypurinol Concentrations Might Be Required for Gouty Patients With Chronic Kidney Disease
TLDR
Higher percentages of patients could meet the treatment goal when their plasma oxypurinol concentrations were higher than the proposed therapeutic range for patients with normal renal function.
Bioequivalence of allopurinol and its metabolite oxipurinol in two tablet formulations
Objective: To test for the bioequivalence of two allopurinol 300 mg tablet formulations (generic allopurinol (Normon) and Zyloric tablets).